ArchiMed takes Instem private (2024)
The healthcare-focused private equity firm ArchiMed bought Instem, a UK maker of software for drug-development and clinical research, for about £203 million. Instem left the London market and went private.
Instem delisted and continued operating under private ownership, free of quarterly reporting.
Another independent drug-development software vendor moved under a specialist healthcare investor.
A near-identical playbook: a specialist healthcare PE firm pulls a niche drug-development software company off public markets.
